Home / News / XenoGesis announces expansion plans with move into BioCity’s Discovery Building

XenoGesis announces expansion plans with move into BioCity’s Discovery Building

Leading DMPK/ADME provider, XenoGesis will be the next tenant to move into BioCity Nottingham’s state-of-the-art Discovery Building, with the support of grant funding from the Government’s Regional Growth Fund and the University of Derby Invest to Grow Programme.

XenoGesis is an independent laboratory-based contract research organisation specialised in preclinical drug metabolism and pharmacokinetics (DMPK), quantitative bioanalysis, in vitro pharmacology and modelling & simulation for human PK and dose prediction. The core XenoGesis team has a proven track record of delivery in drug discovery. Through a consultative approach, the XenoGesis team helps to identify the potential ‘winners’ and ‘losers’ in a selection of compounds synthesised in drug discovery campaigns, providing significant time and cost savings for R&D companies.

XenoGesis will be taking 5,500ft2 on the first floor of the Discovery Building which was officially opened in June 2017. The new space will provide an 83% increase on the existing laboratories and offices that XenoGesis occupies in the Innovation Building.

XenoGesis is working with MCI Consulting’s Brian McInnis, an experienced facilities and project manager, who is overseeing the fit-out of the laboratories and office space whilst ensuring any downtime during the move is kept to an absolute minimum. The move is expected to complete in June.

Commenting on the announcement, Richard Weaver said: “We have identified that the company will continue to grow significantly, and it is clear that there is even more need for a DMPK specialised company that can both advise and deliver. We have grown year on year and our current space within BioCity Nottingham’s Innovation Building is now at capacity. Further expansion would have resulted in staff being split up around the building, or in different buildings, which we wanted to avoid. The recently opened Discovery Building provides us with the ideal space for the next chapter in XenoGesis’ growth.”

He continued: “Having the opportunity to design the laboratories and offices from a blank canvas has allowed us to plan for the future in terms of stream-lining and will also offer an enhanced working environment for the staff. We look forward to welcoming our clients to the new facilities once we have settled in.

“The impact for our clients will be several-fold. As we continue to grow, we will be offering further services, which may have been restricted in our older premises. In addition, we will be growing our global client base, and having the right infrastructure and facilities is key to delivering the best possible service to our clients.”

Established in November 2012, XenoGesis is a BioCity success story. Starting out with a team of three the business has now grown to 25 employees, expanding its laboratory space and investing in state-of-the-art equipment. XenoGesis chose to stay at BioCity because of its infrastructure, business model and ambitious growth plans.

Chief Executive of BioCity, Glenn Crocker, said: “Since starting out at BioCity, XenoGesis has gone from strength to strength. This expansion is yet more evidence of the success of this great company and, I’m sure, the start of a new phase of growth. We are proud to have XenoGesis as an active member of the BioCity community and to be an investor in this high-quality business.”

Mark Wheddon, Head of Delivery at Invest to Grow added: “We are delighted to continue to support XenoGesis with their growth plans and the development of new services to benefit customers, which will see the company expand and the creation of new jobs.”

To find out more about XenoGesis, please click here.

Check Also

Five Life Science companies celebrate success at the Medilink East Midlands Business Awards

Five companies from across the region were delighted to be selected as winners at last …